Device Trial Radar · NCT00593528
PTFE Covered Stents Versus Naked Stents in the TIPS (Transjugular Intra-hepatic Porto-systemic Shunt)
Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
138
Actual
Start
Feb 18, 2008
Primary completion
Jul 11, 2011
Study completion Jul 11, 2011
Sponsor
- Lead sponsor
- University Hospital, ToursAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 15, 2008
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Transjugular intrahepatic portosystemic shunts (TIPS) have been increasingly used for the treatment of complications of portal hypertension in patients with cirrhosis. The initial experiment of the TIPS was reported during the 1990s with stents of various brands, manufacture and sizes, but all "non covered", thus owing the pseudointimal hyperplasia growing inside the stent, which progressively decreases the diameter of the shunt and thus its efficacy. Since the beginning of the 2000s, appeared stents known as "covered" by polytetrafluoroethylene (PTFE) designed to reduce the obstruction rate and thus the frequency shunt revisions. However, these stents are, on average, 2.5 times more expensive than the non covered stents and the cost-effectiveness ratio of the TIPS according to the type of stents used has not been assessed. The aim of this multicentric and randomized study is to assess the cost-effectiveness ratio of these 2 principles of TIPS, the one using stents covered by PTFE, relatively expensive but seldom becoming obstructed, and the other using non covered stents, less expensive than PTFE but requiring regular gestures of redilatation. Population concerned: Patients with a cirrhotic portal hypertension responsible for: * recurrent variceal bleeding * refractory ascite (or hydrothorax)
Conditions
- Cirrhotic Portal Hypertension
Interventions
Naked Stents: Wallstent® (Boston Scientific), Luminexx® (Bard), Zilver® (Cook), Palmaz Genesis® and Smart Control® (Cordis)Device
Vascular Stents
PTFE Covered Stents: Fluency® (Bard), Advanta V12® (Atrium) and Viatorr® (Gore)Device
Vascular Stents
Transjugular intrahepatic portosystemic shunt (TIPS)Procedure
Transjugular intrahepatic portosystemic shunt (TIPS)
Primary outcomes
What the sponsor says the trial is designed to measure.
- TIPS permeability rateTime frame: one year
- Cost of the TIPS and patient care according to the type of stent used brought back to an indicator of effectivenessTime frame: one year
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Chru Bordeaux
Bordeaux, France
Chru Caen
Caen, France
Chru Clermont Ferrand
Clermont-Ferrand, France
9 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.